dc.contributor.author | Tuncer, Samuray | |
dc.contributor.author | Balcı, Özlem | |
dc.contributor.author | Tanyıldız, Burak | |
dc.contributor.author | Kebudi, Rejin | |
dc.contributor.author | Shields, Carol | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T20:02:15Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T20:02:15Z | |
dc.date.issued | 2015 | en_US |
dc.identifier.citation | Tuncer, S., Balcı, Ö., Tanyıldız, B., Kebudi, R. ve Shields, C. (2015). Intravitreal lower- dose (20 mu g) melphalan for persistent or recurrent retinoblastoma vitreous seeds. Ophthalmic Surgery Lasers & Imaging Retina, 46(9), 942-948. https://dx.doi.org/10.3928/23258160-20151008-07 | en_US |
dc.identifier.issn | 2325-8160 | |
dc.identifier.issn | 2325-8179 | |
dc.identifier.uri | https://dx.doi.org/10.3928/23258160-20151008-07 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/3596 | |
dc.description | WOS: 000378842200007 | en_US |
dc.description | PubMed ID: 26469234 | en_US |
dc.description.abstract | BACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 mu g) intravitreal melphalan for VS. PATIENTS AND METHODS: Retrospective review of all patients with active VS treated with lower-dose intravitreal melphalan (20 mu g/0.1 mL) on a monthly basis until complete VS regression was achieved. RESULTS: A total of 14 injections were delivered to seven eyes of seven patients (range: 1-4; median: 2). At a median follow-up of 20 months (range: 12-32 months), complete regression of VS was achieved in all cases (100%), and globe salvage was achieved in six cases (86%). One eye required enucleation for solid tumor recurrence. Side effects of retinal pigment epithelium mottling at the site of injection was noted in two eyes (29%). CONCLUSION: The 2-year results of this study suggest that standard lower-dose (20 mu g) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Slack Incorporated | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Retinoblastoma | en_US |
dc.subject | Intravitreal Melphalan | en_US |
dc.title | Intravitreal lower- dose (20 mu g) melphalan for persistent or recurrent retinoblastoma vitreous seeds | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Ophthalmic Surgery Lasers & Imaging Retina | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-6090-4448 | en_US |
dc.identifier.volume | 46 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.startpage | 942 | en_US |
dc.identifier.endpage | 948 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3928/23258160-20151008-07 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q1 | en_US |